We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Implantable Device for Pulmonary Hypertension Reduces Cardiac Workload and Enhances Blood Flow

By HospiMedica International staff writers
Posted on 04 Mar 2024
Print article
Image: The flexible, gas-filled balloon is placed in the main pulmonary artery and connected by a catheter to a hollow reservoir (Photo courtesy of Aria CV)
Image: The flexible, gas-filled balloon is placed in the main pulmonary artery and connected by a catheter to a hollow reservoir (Photo courtesy of Aria CV)

Pulmonary hypertension is a severe, progressive disease affecting as many as 70 million people globally. It develops when the walls of the pulmonary arteries become rigid, losing their ability to stretch adequately to manage blood flow. Normally, the pressure in the pulmonary arteries of a healthy individual is relatively low. However, in patients with pulmonary hypertension, this pressure increases, and the vessel walls thicken and narrow, impeding blood flow and diminishing vessel elasticity with each heartbeat. This leads to heightened pressure and additional strain on the right side of the heart. Now, a novel implantable device can mimic the function of the healthy vessels by restoring compliance to the pulmonary vessels, thus enabling the heart to pump more blood for less energy. These can improve the ability to exercise while reducing the burden on the heart.

Aria CV’s (St. Paul, MN, USA) Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to reduce the excessive workload on the right heart that can cause right heart failure. The device aims to restore the benefits of a healthy pulmonary artery by reducing cardiac workload and increasing blood flow through the lungs. This novel device offers an alternative treatment for patients who continue to be significantly impacted by right heart dysfunction related to pulmonary hypertension, for which there are limited approved therapy options. The first patient has now been successfully implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial. The ASPIRE PH trial is a feasibility study assessing the initial safety, tolerability, and efficacy of the Aria System under the Food and Drug Administration’s (FDA) Early Feasibility Study Program.

“The successful patient implant of the Gen 2 system is a significant milestone in realizing our mission to improve the lives of those suffering from pulmonary hypertension, a life-threatening disease that can lead to heart failure,” said Dan Gladney, President and CEO of Aria CV. “This procedure is a testament to the dedicated ASPIRE PH team that is providing patients with a novel therapeutic option to treat this deadly condition. If approved, this technology has the potential to be lifesaving and life-changing for thousands of patients with pulmonary hypertension.”

Gold Member
Solid State Kv/Dose Multi-Sensor
Gold Member
12-Channel ECG
Silver Member
Wireless Mobile ECG Recorder
Mechanical Baby Scale
seca 725

Print article


Surgical Techniques

view channel
Image: The endoscopic device can 3D image the stiffness of individual biological cells and complex organisms (Photo courtesy of University of Nottingham)

World’s First Microscopic Probe to Revolutionize Early Cancer Diagnosis

In the early stages of cancer, the cells are significantly softer than normal cells, which facilitates their movement through small spaces and contributes to the rapid spread of the disease, a process... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.